Terms: = Thyroid cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Treatment
37 results:
1. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis.
Gharzai LA; Morris E; Suresh K; Nguyen-Tân PF; Rosenthal DI; Gillison ML; Harari PM; Garden AS; Koyfman S; Caudell JJ; Jones CU; Mitchell DL; Krempl G; Ridge JA; Gensheimer MF; Bonner JA; Filion E; Dunlap NE; Stokes WA; Le QT; Torres-Saavedra P; Mierzwa M; Schipper MJ
Lancet Oncol; 2024 Mar; 25(3):366-375. PubMed ID: 38423050
[TBL] [Abstract] [Full Text] [Related]
2. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
3. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
4. D898_E901
Porcelli T; Moccia M; De Stefano MA; Ambrosio R; Capoluongo E; Santoro M; Hadoux J; Schlumberger M; Carlomagno F; Salvatore D
JCO Precis Oncol; 2023 Aug; 7():e2300052. PubMed ID: 37535881
[TBL] [Abstract] [Full Text] [Related]
5. [Clinicopathological features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma].
Zhu M; Li J; Zheng WH; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):820-826. PubMed ID: 37527987
[No Abstract] [Full Text] [Related]
6. Radiation-Induced Oropharyngeal Squamous Cell Carcinoma: Case Report and Review of the Literature.
Giannini L; Alliata A; Cristofaro V; Incandela F; Pompilio M; Ottini A; Cavalieri S; Nuzzolese I; Iacovelli NA; Franceschini M; Deganello A
Curr Oncol; 2023 Jul; 30(7):6708-6719. PubMed ID: 37504352
[TBL] [Abstract] [Full Text] [Related]
7. p18ink4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer.
Bai F; Liu X; Zhang X; Mao Z; Wen H; Ma J; Pei XH
Cell Cycle; 2023 Jul; 22(13):1637-1653. PubMed ID: 37345432
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
[TBL] [Abstract] [Full Text] [Related]
9. Extratumoral invasion: A unique phenomenon of aggressive recurrent oropharyngeal squamous cell carcinoma.
Seo GT; Greenberg L; Xing MH; Su V; Dowling E; Mundi N; Matloob A; Khorsandi AS; Chai RL; Urken ML; Brandwein-Weber M
Am J Otolaryngol; 2023; 44(2):103756. PubMed ID: 36603379
[TBL] [Abstract] [Full Text] [Related]
10. Microwave Ablation versus Surgical Resection for Solitary T1N0M0 Papillary thyroid Carcinoma.
Wei Y; Niu WQ; Zhao ZL; Wu J; Peng LL; Li Y; Yu MA
Radiology; 2022 Sep; 304(3):704-713. PubMed ID: 35536133
[TBL] [Abstract] [Full Text] [Related]
11. Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
Liao X; Xia X; Su W; Yan H; Ma Y; Xu L; Luo H; Liu W; Yin D; Zhang WH; Chen HN; Deng Y; Ren Z; Yu Z; Liao F; Chen K; Cao M; Zhang Y; Zhang W; Wang W; Zhao JN; Xu H; Shu Y
Gynecol Oncol; 2022 Apr; 165(1):105-113. PubMed ID: 35151492
[TBL] [Abstract] [Full Text] [Related]
12. Anaplastic thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract] [Full Text] [Related]
13. TIGIT/PVR and LncRNA ANRIL dual-targetable PAMAM polymeric nanoparticles efficiently inhibited the hepatoma carcinoma by combination of immunotherapy and gene therapy.
Wang T; Li P; Wan T; Tu B; Li J; Huang F
J Drug Target; 2021 Aug; 29(7):783-791. PubMed ID: 33480288
[TBL] [Abstract] [Full Text] [Related]
14. Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of ink4a/arf repression.
Guo J; Deng N; Xu Y; Li L; Kuang D; Li M; Li X; Xu Z; Xiang M; Xu C
Pharmacol Res; 2021 Feb; 164():105365. PubMed ID: 33307220
[TBL] [Abstract] [Full Text] [Related]
15. p16-positive oropharyngeal cancer with rare thyroid metastasis : A case report.
Suzuki H; Sasaki E; Nishikawa D; Nishikawa D; Koide Y; Beppu S; Terada H; Hanai N
J Med Invest; 2020; 67(1.2):189-191. PubMed ID: 32378605
[TBL] [Abstract] [Full Text] [Related]
16. thyroid hormone induces cellular senescence in prostate cancer cells through induction of DEC1.
Kotolloshi R; Mirzakhani K; Ahlburg J; Kraft F; Pungsrinont T; Baniahmad A
J Steroid Biochem Mol Biol; 2020 Jul; 201():105689. PubMed ID: 32360904
[TBL] [Abstract] [Full Text] [Related]
17. PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human thyroid Cells Overexpressing BRAF V600E Oncogenic Protein.
Putlyaeva LV; Demin DE; Uvarova AN; Zinevich LS; Prokofjeva MM; Gazizova GR; Shagimardanova EI; Schwartz AM
Biochemistry (Mosc); 2020 Jan; 85(1):108-118. PubMed ID: 32079522
[TBL] [Abstract] [Full Text] [Related]
18. Schizandrin A inhibits proliferation, migration and invasion of thyroid cancer cell line TPC-1 by down regulation of microRNA-429.
Ding Q; Li X; Sun Y; Zhang X
Cancer Biomark; 2019; 24(4):497-508. PubMed ID: 30909188
[TBL] [Abstract] [Full Text] [Related]
19. Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.
D'Almeida O; Mothar O; Bondzie EA; Lieumo Y; Tagne L; Gupta S; Volkert T; Levine S; Tagne JB
BMC Cancer; 2019 Feb; 19(1):136. PubMed ID: 30744585
[TBL] [Abstract] [Full Text] [Related]
20. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract] [Full Text] [Related]
[Next]
